The UK BioIndustry Association (BIA) is calling for an extended advance assurance scheme in its response to the UK’s HM Revenue and Customs consultation document on improving access to R&D tax credits for small businesses.
The BIA was closely involved in previous piloting of the service and has welcomed the announcement made by the government in last December’s Autumn Statement that it would introduce the scheme for small businesses making their first claim to R&D tax credits.
It said the HMRC consultation provides a valuable opportunity to input on the administration of the scheme and the BIA response makes clear the benefits for both SMEs and HMRC in extending the benefits of advance assurance beyond a company’s first claim:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze